Elkfork Partners’s Myriad Genetics MYGN Stock Holding History

Elkfork Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$373K	Buy	13,020 +700	+6%	+$20.4K	0.01%	664
2019 Q2	$342K	Buy	12,320 +532	+5%	+$15K	0.01%	689
2019 Q1	$391K	Hold	11,788	–	–	0.01%	625
2018 Q4	$343K	Hold	11,788	–	–	0.01%	622
2018 Q3	$542K	Buy	11,788 +756	+7%	+$33.6K	0.01%	572
2018 Q2	$412K	Hold	11,032	–	–	0.01%	588
2018 Q1	$326K	Buy	11,032 +1,708	+18%	+$57.8K	0.01%	648
2017 Q4	$320K	Buy	9,324 +1,512	+19%	+$51K	0.01%	661
2017 Q3	$283K	Buy	7,812 +1,260	+19%	+$35.9K	0.01%	633
2017 Q2	$169K	Buy	6,552 +2,968	+83%	+$63K	0.01%	743
2017 Q1	$69K	Buy	+3,584	New	+$63.5K	﹤0.01%	839

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Elkfork Partners's MYGN Position: Q3 2019 in Review

Elkfork Partners increased its Myriad Genetics (MYGN) stake by 5.7% in Q3 2019, buying an estimated $20.4K and bringing the position to 13,020 shares worth $373K. The position accounts for 0.01% of the portfolio, ranked #664.

Elkfork Partners first reported a position in MYGN in Q1 2017 and has held it in 11 quarters since. The position peaked at $542K in Q3 2018. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2019.

Elkfork Partners held 13,020 shares of Myriad Genetics worth $373K as of Q3 2019.
Elkfork Partners bought 700 Myriad Genetics shares in Q3 2019, an estimated $20.4K.
Myriad Genetics made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #664 holding.
Elkfork Partners first reported a position in Myriad Genetics in Q1 2017 and has held it in 11 quarters since.
Elkfork Partners's Myriad Genetics position peaked at $542K in Q3 2018.
221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.